Summit Therapeutics PLC Cash Flow-to-Debt Ratio
Summit Therapeutics PLC cash flow-to-debt ratio. Summit Therapeutics PLC (SMMT) has a Cash Flow-to-Debt Ratio of -1.37x as of June 2026, meaning its operating cash flow of $-167.78 Million could theoretically repay -1% of its total liabilities ($122.20 Million) in one year. Check earnings quality score of Summit Therapeutics PLC to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Summit Therapeutics PLC (2003–2025)
Cash flow-to-debt ratio of Summit Therapeutics PLC from 2003 to 2025. Historical debt coverage capacity for Summit Therapeutics PLC across 23 annual periods. Check Summit Therapeutics PLC investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Summit Therapeutics PLC Cash Flow-to-Debt Ratio by Year (2003–2025)
Summit Therapeutics PLC cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Summit Therapeutics PLC. For the full cash flow conversion analysis, see Summit Therapeutics PLC (SMMT) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.50x | $-239.67 Million | $68.52 Million | ▼ -15.2% |
| 2024 | -3.04x | $-113.56 Million | $37.41 Million | ▼ -395.4% |
| 2023 | -0.61x | $-60.74 Million | $99.12 Million | ▼ -692.2% |
| 2022 | -0.08x | $-33.90 Million | $438.18 Million | ▲ +96.8% |
| 2021 | -2.41x | $-53.81 Million | $22.30 Million | ▼ -15.5% |
| 2020 | -2.09x | $-35.34 Million | $16.93 Million | ▼ -12.3% |
| 2019 | -1.86x | $-26.66 Million | $14.34 Million | ▼ -25.7% |
| 2018 | -1.48x | $-35.11 Million | $23.74 Million | ▼ -348.4% |
| 2017 | -0.33x | $-20.58 Million | $62.40 Million | ▼ -211.6% |
| 2016 | 0.30x | $15.18 Million | $51.35 Million | ▲ +106.8% |
| 2015 | -4.36x | $-24.47 Million | $5.62 Million | ▼ -154.7% |
| 2014 | -1.71x | $-16.59 Million | $9.69 Million | ▲ +26.2% |
| 2013 | -2.32x | $-9.68 Million | $4.18 Million | ▼ -10.9% |
| 2012 | -2.09x | $-5.03 Million | $2.41 Million | ▼ -28.5% |
| 2011 | -1.62x | $-3.80 Million | $2.34 Million | ▲ +16.2% |
| 2010 | -1.94x | $-4.34 Million | $2.24 Million | ▼ -277.8% |
| 2009 | -0.51x | $-2.65 Million | $5.15 Million | ▲ +72.9% |
| 2008 | -1.90x | $-14.72 Million | $7.77 Million | ▼ -79.8% |
| 2007 | -1.05x | $-16.13 Million | $15.30 Million | ▼ -11.9% |
| 2006 | -0.94x | $-5.96 Million | $6.33 Million | ▼ -151.8% |
| 2005 | -0.37x | $-931.84K | $2.49 Million | ▼ -540.3% |
| 2004 | 0.08x | $29.74K | $350.21K | ▲ +100.5% |
| 2003 | -17.81x | $-64.97K | $3.65K | — |